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Abstract
Phosphodiesterase inhibitors (PDE5i) have an established role in the treatment of 
erectile dysfunction (ED) and pulmonary arterial hypertension (PAH) but, at the same 
time, they represent a paradigmatic example of a class of drugs, originally tested 
for a clinical indication, shifted to another one, for the unexpected emergence of 
strong evidences opening towards a new market, at that time still to be defined, but 
with an enormous potential. Sildenafil, the primer of PDE5i drugs patented in 1996, 
was designed and thought as anti-hypertensive/anginal, early relocated for ED and 
approved for this in 1998 despite emerging evidences of a further possible use, albeit 
numerically limited, in PAH. The apparent lack of interest in other fields of application 
continue at least until 2004 when, possibly, due to the upcoming of 2 new PDE5i on the 
market, the request for PAH, supported by a trial, was finally submitted and obtained 
by FDA in 2005. It is noteworthy that in medicine, when a relevant cellular mechanism 
is identified and targeted with a new drug, the results are not always predictable 
and/or are in agreement with the interests of the market but serendipity can help. 
Thus development/marketing of drugs is a multifactorial phenomenon that includes, 
also, potential/effectiveness of the molecules, beliefs/curiosity of the researchers, 
doctor/patient expectations, and, first of all, the economical interest related to their 
economic exploitation. In this review we wanted to explore the potentials, if any, of 
PDE5i beyond ED, by searching the literature for off-label applications.
ABBREVIATIONS
cAMP: adenosine 3′,5′-cyclic monophosphate; CAD : 
Coronary Artery Disease; Ca2+: Calcium; ED: Endothelial; FDA: 
Food and Drug Administration; cGMP: Guanosine 3′,5′-cyclic 
monophosphate; GTP: Guanosine 5′ Triphosphate; HF: 
Heart Failure; NO: Nitric Oxide; PAH: Pulmonary Arterial 
Hypertension; PDEs: Cyclic Nucleotide Phosphodiesterase; 
PDE1i: Phosphodiesterase Inhibitors; PDE3i: Phosphodiesterase 
Inhibitors; PDE5i: Phosphodiesterase Inhibitors; PKG: Protein 
Kinase cGMP dependent; QoL: Quality-of-Life; SUPER-1: SUPER-1 
trial (Sildenafil Use in PUlmonary hypER- tension)
INTRODUCTION
Cyclic nucleotide phosphodiesterase (PDEs) superfamily is 
almost ubiquitously distributed in mammalian tissues [1] and 
this because they play an essential role in hydrolyzing Adenosine 
3′,5′-cyclic monophosphate (cAMP) and guanosine 3′,5′-cyclic 
monophosphate (cGMP) to the inactive metabolites AMP and GMP. 
Together with intracellular calcium and Inositol triphosphate 
-that induces the release of calcium from intracellular stores- 
PDEs, through the hydrolysis of cAMP and cGMP, modulate 
intracellular signal transduction. There are most than fourteenth 
different isoforms of PDEs, some of them are selective for cAMP 
and other for cGMP, and this ensures a specific distribution at 
different cellular and sub-cellular levels and regulation of several 
functions. Thus we can find these enzymes in human platelets, 
vascular and bronchial smooth muscle, renal tubules [2], heart, 
brain, pancreas, bladder, urethra, penis, ovary [3] and retina 
[4]. The pattern of tissue distribution of PDEs and their role in 
intracellular signaling support the general interest toward the 
development of specific inhibitors able to prolong or enhance 
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the effects of physiological or counteract pathological processes 
mediated by cAMP or cGMP by inhibition of their degradation. 
After a long period of research and development, started from 
the 1970s, PDEi having an established role are now PDE1i, PDE3i 
and PDE5i that is, undoubtedly, the most successful. It should be 
said that there are at least two non-selective PDEi that should 
be recalled, namely papaverin and teofillin, whose clinical use is 
to contrast the muscle contraction in gastrointestinal tract and 
bronchial airways.  Among the others PDEi, Nimodipine, formally 
an L-type Ca2+ channel antagonist that also inhibits PDE1 activity, 
was originally developed for high blood pressure but it has 
shown potentials in the prevention of vasospasm caused by 
subarachnoid hemorrhage [5]. Milrinon and Amrinon are PDE3 
selective inhibitors, they prevent the degradation of cAMP thus 
they are used for their inotropic effect in heart failure (HF) solely 
in emergency settings [6,7].
Finally PDE5i that are object of this review, by inhibiting PDE5 
they increase intracellular cGMP levels decreasing intracellular 
calcium levels, thereby promoting relaxation of smooth muscle 
cells and other calcium-dependent processes. As we have 
already said PDE5i, starting from Sildenafil, the primer of the 
class, have gained an established role in the treatment of erectile 
dysfunction (ED) and pulmonary arterial hypertension (PAH) 
[8]. The mechanisms of action of PDE5i on the cGMP pathway are 
summarized for convenience in (Figure 1).
Aim of the review
It is beyond this review to celebrate the “myth of the origins” 
and the established properties of the founder of PDE5i class, 
for which we refer to the excellent case history article [9]; 
nonetheless, the evidences on PDE functions and the relevant 
role of PDEi in the modulation of intracellular signaling, clashes 
with the fact that only few PDEi are currently used for a known 
therapeutic indications and, despite the ubiquity of PDE, these 
indications are numerically limited.
Thus we aimed this review to provide a brief historical 
perspective on the development of the PDE5 inhibitors and 
current use focusing on the unrealized potential, if any, of this class 
by retrieving the literature (MedLine) and reporting the number 
of papers, grouped by scope of use of PDE5i, inside and outside 
the commercial license (off-label applications). For the search 
strategy, we used extensively the keyword phosphodiesterase 5 
inhibitors and its acronym to include whole items without setting 
“limits” for article type, availability of text, date of publication, and 
the species studied.
We are aware that the results we report, in terms of matching 
papers, are raw data, including both potential and reality about 
the use of PDE5i since the scope of use cited may be in, many 
cases, merely speculative.
Development of a new anti-hypertensive/anginal 
drug
The history of Sildenafil, the primer of PDE5i, started 
about 30 years ago in Pfizer Central Research’ s laboratories; 
some researchers found that the inhibition of the enzyme 
Phosphodiesterase 5, that is in vascular smooth muscles, reduce 
the vascular tone and platelet aggregation. The first commercial 
inhibitor of PDE5 was indeed Sildenafil (UK-92,480), synthesized 
in the 1980s as a potential treatment for arterial hypertension 
and angina pectoris. The hypothesis was that inhibition of 
PDE5, in heart and blood vessels, could lead to significant 
coronary vasodilation with benefit for patients with coronary 
artery disease (CAD) [10]. After few years of unsatisfactory 
experimentations, some of the patients recruited in this study 
report a pleasant side effect consisting in penile erection (Figure 
2). This side effect that was unexpected, potentially useful, able 
to revolutionize the use of this drug and extend to a potentially 
large number of subjects, led to the closure of its development as 
anti anginal. Indeed Sildenafil in patients with CAD demonstrated 
Figure 1 Cholinergic system determine the production of Nitric Oxide 
(NO) in response to stimulation a Ca2+ pathway in endothelial cells. Ca2+ 
once released activates NO synthesis that diffuses across the smooth-
muscle cell and binds to guanylate cyclase (sGC). Thus the synthesis 
of guanosine 3′,5′-cyclic monophosphate (cGMP) is catalyzed by sGC 
from guanosine 5′ triphosphate (GTP). Then cGMP activates a protein 
kinase cGMP dependent (PKG) which stimulates the uptake of Ca2+ by 
the endoplasmic reticulum of the muscle cell. The reduced levels of 
cytoplasmic calcium cause the muscle cell to relax. 
Figure 2 A joke lampooning the unexpected developments of the 
experimentation with Sildenafil.
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a modest cardiovascular effect, instead the action of PDE5i on 
penile erection in men, determined its fundamental role in the 
therapy of the erectile dysfunction (ED).
An unexpected effect introduces a new indication
Sildenafil, patented in 1996, was relocated for ED and 
approved for this in 1998 by Food and Drug Administration 
(FDA). The marketing of a drug designed for a new clinical 
indication such as ED, inevitably contributes to the arise of a 
clinical problem that was, before, almost neglected following a 
phenomenon known as “disease mongering” [11], a problem 
that is not object of this review. Indeed ED is common in middle-
aged and older men, though not subject to cardiovascular or 
psychiatric problems. It should be remembered that there 
are several organic causes for ED including hypogonadism, 
hyperprolactinemia, pelvic artery diseases and various causes 
of neuropathy; furthermore antipsychotics, antidepressants 
or antihypertensive drugs may cause ED as side effect. Often a 
non-organic cause is identified and the problem is the result of a 
combination of organic and psychological factors, such as sexual 
performance anxiety, which can lead to a vicious circle [12]. In 
this quite complex interplay between organic and non-organic 
causes of ED, the availability of a new class of drugs, with a good 
safety profile and modest side effects, contributed to make PDE5i 
the first choice for ED and a worldwide commercial success. The 
most common side effects are headaches, flushing, and epistaxis 
and these concerned with high tissue concentrations of PDE5. 
The feared risk of Sildenafil to cause orthostatic hypotension in 
subjects with CAD is more relate with the interaction of PDE5 with 
multi-drug antihypertensive therapy. Indeed Sildenafil is a mixed 
vasodilator with a preferential action on veins [13] therefore the 
combination with nitrates could lead to severe vasodilation and 
hypotension. Generally Sildenafil is hemo dynamically safer even 
when added on top of vasoactive treatment [14]. Moreover PDE5i 
has a weak inhibition of PDE6 that is found especially in the 
retina, thus, it is reported a transient blurred vision or difficult 
in discriminating blue-green colors or light sensitivity in course 
of Sildenafil therapy [15]. Eyesight disorder such as non-arteritic 
ischemic optic neuropathy and cilio-retinal artery occlusion are 
signaled in a limited number of case reports [4]. While no proven 
vision-threatening effects were apparent in meta-analyses, minor 
visual effects occur in 3-11% of users and are, either, transient 
or reversible [16]. The commercial success of the first patented 
molecule prompted the development of other PDE5i: Vardenafil, 
Tadalafil, Avanafil. A summary of dosage, pharmacokinetic and 
pharmacodynamic features are reported in (Table 1). These 
drugs received the Food and Drug Administration (FDA) approval 
for the treatment of ED; Sildenafil and Tadalafil were approved 
for the treatment of PAH [17]. Indeed, in the very last years, other 
PDE5i have been synthesized but they will not be mentioned in 
this review.
Beyond erectile dysfunction: pulmonary arterial 
hypertension
Beyond ED, emerging evidences of a possible use of 
Sildenafil, albeit numerically limited, in PAH began to circulate 
in the cardiological community at the beginning of the second 
millennium. When the first case report demonstrating a clinical 
benefit of Sildenafil in PAH was published in 2000 [18], there 
was an apparent lack of interest of the producer in other fields 
of application, at least, until the funding of the SUPER-1 trial 
(Sildenafil Use in PUlmonary hypER- tension) that started to 
enroll patients with PAH, randomized to receive Sildenafil or 
placebo, in 2002 [19]. Before the results of the SUPER-1 were 
published, a randomized, placebo-controlled, double-blind, 
crossover study, started independently on this indication, had 
already been published in 2004 [20]. Thus urged, possibly, by 
the upcoming of 2 new PDE5i on the market and by general 
consensus on the utility of PDE5i in PAH, the request for this 
indication was submitted by the company owner of the molecule 
-with the endorsement of the results of the SUPER-1, finally 
published in The New England- and thus obtained by FDA in 
2005. Indeed, as we have already said, among all the upcoming 
PDE5i, only Tadalafil has followed the same path of Sildenafil and 
obtained the FDA approval for PAH in 2009 [21]; on the same 
indication Vardenafil is now completing a clinical trial.
Unexpressed potentialities in other fields
The safety and high tolerability of PDE5i make them attractive 
drugs to investigate further physiological functions of PDE5. In 
recent years extensive, but very heterogeneous, information 
has been published in this field. A number of other potential 
indications are currently in various phases of preclinical research 
and development. By searching MedLine we have retrieved 
Table 1: Comparison of clinical pharmacokinetics and pharmacodynamics of main PDE5i.
Sildenafil Tadalafil Vardenafil Avanafil
Available doses (mg) 25-50-100 5-10-20 2.5-5-10-20 50-100-200
Effectiveness 60 min 15-30 min 30 min 15-30 min
Lasting
(hours)
4-8 h 24-36 h 2-8 h 1-6 h
Food
interaction
high-fat Not significant high-fat Not significant
Alcohol interaction None None None None
Active metabolites N-desmethylation None Desmethylation Methylation, 
glucuronidation
Cytochrome
P isoenzymes
3A4, 2C9, 2C19 and 2D6 3A4 3A4, 3A5, 2C9 3A4,2C
Excretion
77-88% feces; minor in 
urine
70% feces;
30% urine
91-95% feces; minor in 
urine
62% in feces;
21% urine
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3701 papers on PDE5i; among them the main uses have been 
grouped into five categories, according to standard nosology, 
and reported by relevance: a- Urological disease and alterations 
in sexual function and reproduction; b- Cardiovascular diseases 
and endothelial dysfunction; c- Central nervous system disorders; 
d- cancer, in e- other uses in which we have included recreational 
use, sports and jet lag.
In Table (2) the results are summarized reporting the 
absolute numbers of matching documents.
Urological disease and alterations in sexual function and 
reproduction: This group is the most numerous since it includes 
the main approved indication for PDE5i; we have counted 1966 
papers representing more than 53% of the total.
Among them, ED represents alone more than 49% of the 
total since others uses/indications are, indeed, a minority which 
stands on 4%; these uses are almost off-label and none of them 
have been studied in a clinical trial. Actually the only use of PDE5i 
beyond ED, supported by the American Urological Association, 
without strong evidences, is as alternative treatment, in 
combination therapy with alpha adrenergic antagonists, for the 
treatment of moderate to severe symptoms of benign prostatic 
hyperplasia [22].
Cardiovascular diseases and endothelial dysfunction: 
Numerically this group ranks second, including 1597 published 
papers, representing more than 43% of the total. Not surprisingly 
PAH, the secondary approved indication for PDE5i, alone accounts 
1050 papers that are more than 28% of the total. This possibly 
because PDE5i were firstly developed as anti-hypertensive/ 
anginal and several studies were conducted in such therapeutical 
hypothesis. Furthermore, to treat endothelial dysfunction, that 
is at a major crossroads in cardiovascular pathophysiology, still 
make sense even if the optimism generated by pioneering studies 
in such field have not been confirmed beyond PAH.
Among the factors mediating cardiovascular disease and 
metabolic disorders that are, possibly, linked to PDE5 activity 
[23], cytokines and chemokines are a good candidate, they are 
small redundant proteins that, indeed, play an essential role in 
cell signaling by exhibiting a complex pattern of activation [24] 
that results in the reporting and management of cellular damage 
by modulating inflammation processes. Cardiovascular and 
metabolic diseases, mainly if a remodeling process is in fact, often 
exhibits pro-inflammatory cytokines, in such respect a possible 
role of PDE5i as a specific modulator of the inflammatory 
response, has been demonstrated in diabetic cardiomyopathy 
[25]. This possible effect could, also, support the favorable data 
observed in HF. The first data about the use of Sildenafil in 
patients with HF, preserved ejection fraction (HFpEF) and PAH 
have been published previously demonstrating that in the treated 
group a significant favorable reduction of alveolar-capillary 
membrane resistance, diminished pulmonary vascular tone, 
improved aerobic and ventilatory efficiency which lasted one 
year [26]. Unfortunately a subsequent randomized trial failed to 
demonstrate any significant differences between the two groups 
in the combined primary end points that were, indeed, many: 
change in peak oxygen consumption at 24 weeks, cardiovascular 
or renal hospitalization, pulmonary artery pressures, or quality-
of-life (QoL) base on Minnesota Questionnaire [27]. Despite 
these results, it should be remembered that almost 80% of 
HFpEF patients already have PAH and the echocardiographic 
estimation of pulmonary pressures could help to definite the 
clinical prognosis [28]. Thus, after a comprehensive evaluation of 
the patients with HFpEF, the presence of PAH may still justify the 
use of PDE5i.  Since this is still an active field of research, a 
new, randomized, placebo-controlled study failed to demonstrate 
that Sildenafil treatment could improve cardiovascular structure 
and function, cardiopulmonary exercise tests, or health-related 
QoL health measurements, however, the same authors suggest 
that the treatment period was limited to observe significant 
cardiac effects [29].
Central nervous system disorders: Numerically the papers 
in this group represent an absolute minority since we have 
found only 47 papers representing the 1.3% of the total. All the 
uses reported are, indeed, off-label; Sildenafil, Vardenafil, and 
Tadalafil has been shown to ameliorate the cognitive function 
and, possibly, to enhance synaptic plasticity [30-32] suggesting a 
possible role in Alzheimer’s disease [33].
Cancer: Since PDE5 is expressed in different cancers, the 
prospect of a possible application of PDE5i, although controversial 
in some respects, is still attractive. The studies aimed at this 
scope represent only a minority of published papers; we have 
found only 10 papers, that is to say about the 0.3% of the total. 
The studies retrieved are all pre-clinical, the main effect of PDE5i 
Table 2: References retrieved from MedLine quoting the use of PDE5i 
for a specific application/indication.
Use/indication
[obtained from keywords]
Retrieved 
n°
vs 
Total
%
Erectile disfunction † 1836 49.61%
Pulmonary Hypertension † 1050 28.37%
Heart Failure 248 6.70%
diabetic peripheral neuropathy 220 5.94%
Female Sexual Dysfunction 65 1.76%
Raynaud's phenomenon ‡ 46 1.24%
Stroke 31 0.84%
Sports 28 0.76%
Premature ejaculation 27 0.73%
Recreational use 24 0.65%
Preeclampsia 22 0.59%
Priapism 17 0.46%
Learning and memory 16 0.43%
Overactive Bladder and Incontinence 15 0.41%
Resistant Hypertension 11 0.30%
Cancer 10 0.27%
high-altitude Pulmonary edema 9 0.24%
Peripheral artery disease 8 0.22%
Peyronie’s disease 8 0.16%
Benign Prostate Syndrome/Lower Urinary 
Tract Symptoms BPS/LUTS ‡
5 0.14%
high-altitude Pulmonary hypertension 5 0.14%
Jet lag 2 0.05%
† Drugs approved for the corresponding use; ‡ General consensus for 
the use, not yet approved by FDA.
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in selected carcinomas, such as breast, colon, bladder an lung, 
was a reduction in the tumor volume which mechanism seems to 
be linked to a pro-apoptotic effect and to the inhibition of cellular 
proliferation and angiogenesis [34]. A further possible effect was 
the enhancement of the effects of chemotherapy in brain tumor 
models [35] and prostate cancer. A possible role in the treatment 
of malignancies of the hematopoietic and lymphoid tissues, with 
particular reference to B-Chronic lymphocytic leukemia, has 
been demonstrated in vitro studies [36]. Nonetheless in selected 
cancers such as brain ones and melanomas, an inverse correlation 
between PDE5 levels and invasiveness was reported [37].
Other uses: In other uses we have grouped the papers 
retrieved in which we have found, as uses, recreational, sport 
and jet lag one. They represent an absolute minority of the total, 
accounting 45 published papers, about the 1.2% of the total. 
However, it should be said that the recreational use, ranking a 
minority of published articles (24 papers; 0.6% of the total) has, 
on the contrary, a huge popular success since a survey published 
in J Sex Med reports that about 21% of healthy men, aged 18-30 
years, have used PDE5i as a recreational drug without medical 
control [38].
Although the papers supporting off-label uses of PDE5i are 
indeed a minority, it is impossible to say that Sildenafil (and other 
similar drugs), are always used inside the commercial license and 
following standard medical criteria or control.
In Figure (3) are visualized minor uses of PDE5i.
DISCUSSION AND CONCLUSION
Notwithstanding the huge of paper celebrating the effects 
of PDE5i “beyond” ED, we must admit that the indications 
“passed” into the real word and approved are very few, as we 
can count them with one hand. This is an inherent limitation of 
the underlying model targeting PDE5 and/or of the molecule 
or is the result of the planetary success of PDE5i for ED that 
steals space to any other possible use? Thus it was nontrivial to 
quantify any “other” use of PDE5i. By considering the number of 
papers published in various indications as a form of interest and/
or consensus, before and after any official approval, our results 
suggests that the main secondary field of application is, currently, 
the cardiovascular one (43%) and this is supported by the fact 
that the PDE5i were thought to target vessels. Unfortunately the 
treatment of PAH, that alone accounts more than 28% of the total, 
is the only secondary indication now approved. The reported 
studies dealing with other uses (n:815; 22% of total) are actually 
off-label, therefore we are not allowed to hypothesize a role of 
PDE5i except some emerging evidences on possible applications 
in benign prostate syndrome, HF with preserved ejection fraction, 
Alzheimer and cognitive diseases.
Thus the potential of PDE5i can be considered exhausted? 
It is reasonable to expect more by enlarging the perspective 
towards other PDEs? Indeed the PDE super family is ubiquitously 
distributed in eukaryotes, thus it still represents a good 
opportunity to develop new therapeutic approaches, especially 
in emerging diseases. One of the possibilities is certainly 
to target, with a molecular approach, specific PDE subtypes, in 
physiological and pathological states, to revamp the therapeutic 
approach to intracellular signaling. 
In conclusion, the lesson we have learned from the 
paradigmatic case of Sildenafil is that the development and the 
marketing of drugs is a complex multi factorial phenomenon 
that includes: 1- the potential and effectiveness of the molecules, 
2- the beliefs and, often, the curiosity of the researchers, 3- the 
relationship between doctor and patient in terms of expectations 
and, last but first of all, 4- the economical interest related to 
their economic exploitation and the patent protection strategies. 
In each of the above steps, we can say, without doubt, that 
serendipity, still, can help [39]. Finally, a question that deserves 
Figure 3 A line bar graph showing minor uses of PDE5i reported in the papers retrieved from MedLine. The scale reports the absolute number of 
papers for each indications.
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a further elucidation is whether an extensive and, indeed, very 
profitable economic exploitation of a drug, focused to a specific 
use, steals space to any other possible uses making re-marketing 
a hard issue?
LIMITATIONS OF THE REVIEW
This study has several limitations that should be 
acknowledged. Firstly, the key words used are assumed as 
reference, only documents matching are thus included; secondly, 
a paper describing an off-label use does not necessarily support 
a possible future clinical use; thirdly, MedLine is continuously 
expanding, thus our data our data refer to April 2017.
REFERENCES 
1. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional 
implications of multiple isoforms. Physiol Rev. 1995; 75: 725-748.
2. Nagiub M, Filippone S, Durrant D, Das A, Kukreja RC. Long-acting PDE5 
inhibitor tadalafil prevents early doxorubicin-induced left ventricle 
diastolic dysfunction in juvenile mice: potential role of cytoskeletal 
proteins. Can J Physiol Pharmacol. 2017; 95: 295-304. 
3. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, 
et al. Isolation and characterization of cDNAs encoding PDE5A, 
a human cGMP-binding, cGMP-specific 3’,5’-cyclic nucleotide 
phosphodiesterase. Gene. 1998; 216: 139-147. 
4. Ramasamy B, Rowe F, Nayak H, Peckar C, Noonan C. Acute angle-
closure glaucoma following sildenafil citrate-aided sexual intercourse. 
Acta Ophthalmol Scand. 2007; 85: 229-230. 
5. Allen GS, Ahn HS, Preziosi TJ, Battye R, Boone SC, Chou SN, et al. 
Cerebral arterial spasm--a controlled trial of nimodipine in patients 
with subarachnoid hemorrhage. N Engl J Med. 1983; 308: 619-624. 
6. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis 
SM, et al. Effect of oral milrinone on mortality in severe chronic heart 
failure. The PROMISE Study Research Group. N Engl J Med. 1991; 325: 
1468-1475. 
7. Benotti JR, Grossman W, Braunwald E, Davolos DD, Alousi AA. 
Hemodynamic assessment of amrinone. A new inotropic agent. N Engl 
J Med. 1978; 299: 1373-1377. 
8. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. 
Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study 
Group. Sildenafil citrate therapy for pulmonary arterial hypertension. 
N Engl J Med. 2005; 353: 2148-2157. 
9. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to 
erectile dysfunction to pulmonary hypertension and beyond. Nat Rev 
Drug Discov. 2006; 5: 689-702. 
10. Chrysant SG. Effectiveness and safety of phosphodiesterase 5 
inhibitors in patients with cardiovascular disease and hypertension. 
Curr Hypertens Rep. 2013; 15: 475-483. 
11. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical 
industry and disease mongering. BMJ. 2002; 324: 886-891. 
12. Fanni E, Castellini G, Corona G, Boddi V, Ricca V, Rastrelli G, et al. 
The Role of Somatic Symptoms in Sexual Medicine: Somatization as 
Important Contextual Factor in Male Sexual Dysfunction. J Sex Med. 
2016; 13: 1395-1407. 
13. Chrysant SG. Effectiveness and safety of phosphodiesterase 5 
inhibitors in patients with cardiovascular disease and hypertension. 
Curr Hypertens Rep. 2013; 15: 475-483. 
14. Ciulla MM, Nicolini P, Benfenati C, Vecchiato C, Acquistapace G, 
Perrucci GL, et al. Limited hypotensive effect of sildenafil in a high-
risk population: a preliminary report. Curr Drug Saf. 2011; 6: 219-223. 
15. Mehrotra N, Gupta M, Kovar A, Meibohm B. The role of pharmacokinetics 
and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int 
J Impot Res. 2007; 19: 253-264. 
16. Azzouni F, Abu samra K. Are phosphodiesterase type 5 inhibitors 
associated with vision-threatening adverse events? A critical analysis 
and review of the literature. J Sex Med. 2011; 8: 2894-2903. 
17. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. 
Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl 
J Med. 2005; 353: 2148–2157.
18. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil l in primary pulmonary 
hypertension. N Engl J Med. 2000; 343: 1342.
19. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. 
Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study 
Group. Sildenafil citrate therapy for pulmonary arterial hypertension. 
N Engl J Med. 2005; 353: 2148-2157. 
20. Sastry BK, Narasimhan C, Reddy NK, Raju BS. Clinical efficacy of 
sildenafil in primary pulmonary hypertension: a randomized, placebo-
controlled, double-blind, crossover study. J Am Coll Cardiol. 2004; 43: 
1149-1153.
21. Nazzareno Galiè, Bruce H. Brundage, Hossein A. Ghofrani, Ronald J. 
Oudiz, Gerald Simonneau, Zeenat Safdar, et al. Tadalafil therapy for 
pulmonary arterial hypertension. Circulation. 2009; 119: 2894–2903.
22. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, et 
al. Characterization of phosphodiesterase type 5 expression and 
functional activity in the human male lower urinary tract. J Sex Med. 
2010; 7: 59-69. 
23. Corinaldesi C, Di Luigi L, Lenzi A, Crescioli C. Phosphodiesterase type 
5 inhibitors: back and forward from cardiac indications. J Endocrinol 
Invest. 2016; 39: 143-151. 
24. Ciulla MM, De Marco F, Montelatici E, Lazzari L, Perrucci GL, Magrini 
F. Assessing cytokines’ talking patterns following experimental 
myocardial damage by applying Shannon’s information theory. J 
Theor Biol. 2014; 343: 25-31.
25. Di Luigi L, Corinaldesi C, Colletti M, Scolletta S, Antinozzi C, Vannelli 
GB, et al. Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the 
Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and 
in Subjects with Diabetic Cardiomyopathy. Inflammation. 2016; 39: 
1238-1252. 
26. Guazzi M, Tumminello G, Di Marco F, Fiorentini C, Guazzi MD. The 
effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary 
hemodynamics and diffusion capacity, exercise ventilatory efficiency, 
and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol. 
2004; 44: 2339-2348. 
27. Hussain I, Mohammed SF, Forfia PR, Lewis GD, Borlaug BA, Gallup DS, 
et al. Impaired Right Ventricular-Pulmonary Arterial Coupling and 
Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: 
An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to 
Improve Clinical Status And Exercise Capacity in Diastolic Heart 
Failure (RELAX) Trial. Circ Heart Fail. 2016; 9: e002729.
28. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield 
MM. Pulmonary hypertension in heart failure with preserved ejection 
fraction: a community-based study. J Am Coll Cardiol. 2009; 53: 1119-
1126. 
29. Liu LC, Hummel YM, van der Meer P, Berger RM, Damman K, van 
Veldhuisen DJ, et al. Effects of sildenafil on cardiac structure and 
function, cardiopulmonary exercise testing and health-related quality 
of life measures in heart failure patients with preserved ejection 
fraction and pulmonary hypertension. Eur J Heart Fail. 2017; 19: 116-
125.
30. Cuadrado-Tejedor M, Hervias I, Ricobaraza A, Puerta E, Pérez-Roldán 
Central
Bringing Excellence in Open Access


Ciulla et al. (2017)
Email: 
JSM Sexual Med 2(1): 1005 (2017) 7/7
Ciulla MM, Vivona P (2017) PDE5 Inhibitors, Erectile Dysfunction and beyond: How, Sometimes, Indications are the Consequences of Marketing Strategies and/
or Serendipity. JSM Sexual Med 2(1): 1005.
Cite this article
JM, García-Barroso C, et al. Sildenafil restores cognitive function 
without affecting β-amyloid burden in a mouse model of Alzheimer’s 
disease. Br J Pharmacol. 2011; 164: 2029-2041.
31. García-Barroso C, Ricobaraza A, Pascual-Lucas M, Unceta N, Rico 
AJ, Goicolea MA, et al. Tadalafil crosses the blood-brain barrier 
and reverses cognitive dysfunction in a mouse model of AD. 
Neuropharmacology. 2013; 64: 114-123.
32. Reneerkens OA, Rutten K, Akkerman S, Blokland A, Shaffer CL, Menniti 
FS, et al. Phosphodiesterase type 5 (PDE5) inhibition improves object 
recognition memory: indications for central and peripheral mecha- 
nisms. Neurobiol Learn Mem. 2012; 97: 370-379.
33. Sánchez-Arias JA, Rabal O, Cuadrado-Tejedor M, de Miguel I, Pérez-
González M, Ugarte A, et al. Impact of Scaffold Exploration on Novel 
Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors 
for the Treatment of Alzheimer’s Disease. ACS Chem Neurosci. 2017; 
8: 638-661. 
34. Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, et al. Sulindac 
selectively inhibits colon tumor cell growth by activating the cGMP/
PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther. 
2013; 12: 1848-1859. 
35. El-Naa MM, Othman M, Younes S. Sildenafil potentiates the antitumor 
activity of cisplatin by induction of apoptosis and inhibition of 
proliferation and angiogenesis. Drug Des Devel Ther. 2016; 10: 3661–
3672.  
36. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. 
Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, 
induce caspase-dependent apoptosis of B-chronic lymphocytic 
leukemia cells. Blood. 2003; 101: 265-269. 
37. Hu J, Ljubimova JY, Inoue S, Konda B, Patil R, Ding H, et al. 
Phosphodiesterase type 5 inhibitors increase Herceptin transport and 
treatment efficacy in mouse metastatic brain tumor models. PLoS One. 
2010; 5: e10108. 
38. Bechara A, Casabé A, De Bonis W, Helien A, Bertolino MV. Recreational 
use of phosphodiesterase type 5 inhibitors by healthy young men. J 
Sex Med. 2010; 7: 3736-3742. 
39. Eder J, Herrling PL. Trends in Modern Drug Discovery. Handb Exp 
Pharmacol. 2016; 232: 3-22. 
